NEWS

HitGen and Aduro Enter Research Collaboration

Wednesday, Aug 16, 2017

HitGen Ltd announced that the company has entered into a multi-target multi-year collaboration with Aduro Biotech Inc , to discover novel small molecule leads for multiple therapeutic targets of interest to Aduro. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library (DEL) design, synthesis and screening to discover novel leads which will be licensed exclusively to Aduro. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from Aduro.

“We are delighted to enter this collaboration with Aduro, one of the leading biotech companies in the immuno oncology field in the world. We will work closely with Aduro scientists to help generate new and more effective therapeutics for patients” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.

 

Source: businesswire.com

Other News